FORMS · BIOAVAILABILITY
Sermorelin tablets vs injection: what the research notes
Why oral and sublingual peptide products are criticized, and what the pharmacokinetic record actually shows about delivery.
The short version
If you are comparing sermorelin tablets to injectable sermorelin, the research points in one direction on delivery. Sermorelin is a peptide — a short chain of amino acids — and peptides are broken down by digestive enzymes in the gut and absorbed poorly across the lining of the mouth or nose. That is why essentially all of the human studies used injection, not pills or drops [1][2][3].
The single most relevant number is from a pharmacokinetic study: when GHRH(1-29) was given intranasally, only about 3-5% of it reached the bloodstream [3]. Oral and sublingual absorption faces the same basic obstacle. This page lays out what the record says about forms, without recommending any product, any source, or any dose. Where the published data exist, they are for the injected routes.
Why sermorelin tablets and sublingual products are criticized
Oral, sublingual, and troche "sermorelin" formulations are widely criticized in research-user communities as ineffective, and the criticism has a mechanistic basis rather than being mere opinion [3]. Peptides like GHRH(1-29) are degraded in the gastrointestinal tract and absorbed poorly across mucosal surfaces. The clearest published anchor is the intranasal pharmacokinetic finding: bioavailability of only ~3-5% by that mucosal route [3].
If a mucosal route delivers only a small single-digit percentage of the dose to circulation, a swallowed tablet — which also faces stomach acid and digestive enzymes — has no obvious reason to do better, and typically does worse. The published efficacy that exists for sermorelin — pediatric growth acceleration [1] and the GH/IGF-1 reversal in older men [2] — was generated with subcutaneous injection, not tablets. There is no comparable controlled efficacy record for oral or sublingual sermorelin.
What the injected record establishes instead
By contrast, the injected record is substantial. Subcutaneous sermorelin accelerated linear growth in growth-hormone-deficient children, raising first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. Subcutaneous GHRH(1-29) twice daily for 14 days reversed age-related GH and IGF-1 decreases in older men [2]. Intravenous dosing characterized the dose-response and the ~3-hour duration of GH elevation despite rapid clearance [3].
Sermorelin is supplied as a lyophilized powder reconstituted with sterile diluent and refrigerated, because aqueous peptide solutions degrade [3][9]. For the administration record on the injectable route, see the sermorelin injection page; for the regulatory standing of compounded sermorelin, see the legal status page. This page does not endorse, source, or price any formulation — it summarizes what the literature notes about how the molecule is, and is not, effectively delivered.
How to read a tablet claim against the record
When a product is described as oral or sublingual "sermorelin," the useful question is not whether it contains the peptide but whether any meaningful amount of it survives to reach the bloodstream. The published anchor for that question is the route data: an intranasal pharmacokinetic study measured bioavailability at only ~3-5% [3]. A swallowed tablet faces an even harsher path — stomach acid and a wall of digestive enzymes designed to break peptides into their building blocks — so there is no published basis to expect a tablet to outperform that already-low mucosal figure.
The broader peptide-therapeutics literature reflects the same caution. A 2026 review of therapeutic peptides in metabolic and endocrine conditions concludes that, while peptides are a promising class, most newer, unapproved peptides still need further study before they can be used safely and predictably in humans — a statement about evidence, formulation, and supply, not just the molecule itself [10]. None of this is a verdict on any specific product; it is the framework the published record provides for weighing one.
What this means for the tablets-vs-injection question
Put plainly: the human evidence that exists for sermorelin — pediatric growth acceleration [1], the GH/IGF-1 reversal in older men [2], and the dose-response and ~3-hour GH elevation characterized pharmacokinetically [3] — was all generated with injection. There is no comparable controlled efficacy dataset for tablets, sublingual drops, or troches.
That asymmetry is the whole of the tablets-vs-injection comparison as the literature stands. It is not that tablets have been tested and found weaker; it is that the route which the body absorbs poorly was never the route the efficacy data came from. A careful reader treats injected-route findings as the ones with evidence behind them, and treats oral-route claims as unsupported by the controlled record [3]. For the administration side of the injected route, see the sermorelin injection page; for where compounded sermorelin sits with the FDA, see the legal status page.